PMID- 36843256
OWN - NLM
STAT- MEDLINE
DCOM- 20230829
LR  - 20230829
IS  - 1874-6128 (Electronic)
IS  - 1874-6098 (Linking)
VI  - 16
IP  - 3
DP  - 2023
TI  - A Long-term Study of NeuroAid (MLC601, MLC901) in Patients with Alzheimer's 
      Disease; An Extension 8-year Follow-up Study.
PG  - 234-239
LID - 10.2174/1874609816666230224111759 [doi]
AB  - BACKGROUND: MLC601 and MLC901 showed neuroprotective and neuroregenerative 
      properties and positive results in the treatment of dementia and cognitive 
      impairment. This study aimed to investigate the long-term benefits of monotherapy 
      with MLC601 and MLC901 in patients with Alzheimer's disease (AD). METHODS: In 
      this study, patients with AD, diagnosed by DSM-IV criteria, were enrolled. 
      Patients have received MLC601 for four years, and their regimen has changed to 
      MLC901 for another four years. Recruited patients were followed to assess the 
      efficacy and safety first of MLC601 and MLC901. Mini-Mental State Examination 
      (MMSE) and Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog) 
      were used to assess cognitive function. Safety was evaluated by monitoring 
      adverse events (AEs) and abnormal findings in physical examinations or lab tests. 
      RESULTS: At the end of the trial, the changes in the mean (+/-SD) MMSE and ADAS-Cog 
      scores were 5.1 (3.09) and 12.5 (10.89), respectively. Both scores showed a 
      significant change in repeated measure analysis, with the ADAS-Cog score 
      indicating a higher change than the MMSE score (P < 0.001). CONCLUSION: For more 
      than eight years, we studied monotherapy with NeuroAid (MLC601, MLC901) in 
      patients with AD. The study contributes further to the long-term safety and 
      efficacy data of MLC in patients with AD.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Pakdaman, Hossein
AU  - Pakdaman H
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Amini Harandi, Ali
AU  - Amini Harandi A
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Gharagozli, Koroush
AU  - Gharagozli K
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Siavoshi, Fatemeh
AU  - Siavoshi F
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Shirzadeh Barough, Siavash
AU  - Shirzadeh Barough S
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Sharifipour, Ehsan
AU  - Sharifipour E
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Esfandani, Akram
AU  - Esfandani A
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Ilkhani, Saba
AU  - Ilkhani S
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Tabatabaei, Fatemeh Sadat
AU  - Tabatabaei FS
AD  - Department of Neurology, Brain Mapping Research Center, Shahid Beheshti 
      University of Medical Sciences, Tehran, Iran.
FAU - Sobhanian, Seyed Ali
AU  - Sobhanian SA
AD  - Department of Neurology, Islamic Azad University Tehran Medical Sciences, Tehran, 
      Iran.
LA  - eng
SI  - ClinicalTrials.gov/NCT01696123
PT  - Clinical Trial
PL  - United Arab Emirates
TA  - Curr Aging Sci
JT  - Current aging science
JID - 101473576
RN  - 0 (Neuroaid)
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/diagnosis/drug therapy/psychology
MH  - Follow-Up Studies
MH  - *Drugs, Chinese Herbal
MH  - *Cognitive Dysfunction
OTO - NOTNLM
OT  - ADAS-Cog
OT  - Alzheimer's disease
OT  - MLC601
OT  - MLC901
OT  - dementia
OT  - neuroregenerative
EDAT- 2023/02/28 06:00
MHDA- 2023/08/29 12:44
CRDT- 2023/02/27 01:09
PHST- 2022/09/01 00:00 [received]
PHST- 2023/01/09 00:00 [revised]
PHST- 2023/01/23 00:00 [accepted]
PHST- 2023/08/29 12:44 [medline]
PHST- 2023/02/28 06:00 [pubmed]
PHST- 2023/02/27 01:09 [entrez]
AID - CAS-EPUB-129792 [pii]
AID - 10.2174/1874609816666230224111759 [doi]
PST - ppublish
SO  - Curr Aging Sci. 2023;16(3):234-239. doi: 10.2174/1874609816666230224111759.